Cybin (OTCQB: CLXPF) is a life sciences company at the forefront of the revolution in mental health therapeutics and is developing a new class of psychedelic medicines and treatment protocols, with the goal of becoming the leader in psychedelic therapeutics for mental well-being. CEO Douglas Drysdale joins us to discuss the company's unique and non-traditional approach to treat mental and neurological disorders.